Figures
Abstract
We have designed and tested a new way to selectively deliver HPMA polymer-coated adenovirus type 5 (Ad5) particles into matrix metalloproteinase (MMP)-overexpressing tumor cells. An activatable cell penetrating peptide (ACPP) was designed and attached to the reactive 4-nitrophenoxy groups of HPMA polymers by the C-terminal amino acid (asparagine, N). ACPPs are activatable cell penetrating peptides (CPPs) with a linker between polycationic and polyanionic domains, and MMP-mediated cleavage releases the CPP portion and its attached cargo to enable cell entry. Our data indicate that the transport of these HPMA polymer conjugates by a single ACPP molecule to the cytoplasm occurs via a nonendocytotic and concentration-independent process. The uptake was observed to finish within 20 minutes by inverted fluorescence microscopy. In contrast, HPMA polymer-coated Ad5 without ACPPs was internalized solely by endocytosis. The optimal formulation was not affected by the presence of Ad5 neutralizing antibodies during transduction, and ACPP/polymer-coated Ad5 also retained high targeting capability to several MMP-overexpressing tumor cell types. For the first time, ACPP-mediated cytoplasmic delivery of polymer-bound Ad5 to MMP-overexpressing tumor cells was demonstrated. These findings are significant, as they demonstrate the use of a polymer-based system for the targeted delivery into MMP-overexpressing solid tumors and highlight how to overcome major cellular obstacles to achieve intracellular macromolecular delivery.
Citation: Li S, Chen J, Xu H, Long J, Xie X, Zhang Y (2014) The Targeted Transduction of MMP-Overexpressing Tumor Cells by ACPP-HPMA Copolymer-Coated Adenovirus Conjugates. PLoS ONE 9(7): e100670. https://doi.org/10.1371/journal.pone.0100670
Editor: Matthew Bogyo, Stanford University, United States of America
Received: August 13, 2013; Accepted: May 30, 2014; Published: July 7, 2014
Copyright: © 2014 Li et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded by the National Nature Science Foundation of China (grant Nos. 30971146 and 81201960). This work was also supported by Interna- tional Cooperation and Exchanges Projects of Guangdong Province, China (No. 2010B050700023) and Medical Scientific Research Foundation of Guangdong Province, China (No. A2013244). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Adenovirus (AdV) is a widely used vector for cancer gene therapy because of its capacity for transgene expression in both dividing and nondividing cells [1]–[4]. However, when they are to be delivered intravenously to treat primary tumor or metastatic disease, the wide tissue distribution of the coxsackie and adenovirus receptor (CAR, the primary receptor for adenovirus type 5) precludes target selectivity, and neutralization of adenovirus by pre-existing antibodies can ablate the delivery. Further, the virus can provoke immune responses which prevents repeated dosing and limits the duration of therapeutic gene expression [5], [6]. These factors have largely limited therapeutic use of adenovirus to local or direct administration. A useful viral gene therapy vector should be protected from neutralizing antibodies and enable delivery to target cells.
Addressing these challenges necessitates alternative approaches to redirect AdV type 5 (Ad5) for CAR-independent cellular internalization. Synthetic materials such as cationic lipids and cationic polymers have been used to modify AdV to improve cellular uptake [7]–[14]. However, pEGylated virus still exhibits CAR-mediated infection, which results in nonspecific membrane activity [15]–[17]. Thus, hydrophilic poly-[N-(2-hydroxypropyl) methacrylamide] (pHPMA) has received attention as a more attractive polymer for this purpose. A previous study showed that pHPMA is the optimal means of modification, as it ablates normal pathways of Ad5 infection completely, prolongs the circulation time in blood [18], increases the accumulation of Ad5 by the EPR (enhanced permeability and retention) effect [19] and permits incorporation of a range of targeting molecules and biological effectors to enhance properties such as programming tropism, as well as tissue penetration [20]–[30]. To the best of our knowledge, a detailed investigation of pHPMA modification used to potentiate Ad5 infection and target solid tumor cells has not been reported.
We report here the development of a covalent coating and retargeting strategy using a multivalent hydrophilic polymer based on poly-[N-(2- hydroxypropyl) methacrylamide] (pHPMA) and activatable cell-penetrating peptides (ACPPs). Cell-penetrating peptides (CPPs) are peptides that can translocate through the cellular membranes, such as TAT, Antp, VP22, and polyarginine [31]–[35], and are being used to deliver various cargoes into the cell, including proteins, DNA, antibodies, toxins and nanoparticulate drug carriers (including pHPMA) [36]–[44]. ACPPs are polycationic peptides (polyarginine) which are neutralized by polyanionic (polyglutamic acid) sequences through the fusion of cleavable linkers. Only in the immediate vicinity of extracellular proteases [matrix metalloproteinases (MMPs)] in tumors are ACPPs released from the polycationic peptides, allowing their cargo to attach to and enter cells. Because MMP-2 and MMP-9 are proteases mostly overexpressed by tumors, they were chosen as the initial primary targets [45]–[52]. Incorporation of targeting ACPPs onto the polymer-coated virus enables CPP-mediated and CAR-independent binding and uptake into cells overexpressing MMPs. Thus, ACPPs are an effective means of altering viral tropism and targeting tumor cells. Based on the selective local targeting and activation of CPPs, multivalent polymeric modification of adenovirus may provide the ability to retarget viruses to infect human carcinoma cells. As a non-genetic process, the technology is simple, versatile and should yield viruses with an improved safety profile.
Materials and Methods
Chemicals
5-or6-(N-Succini- midyloxycarbonyl)-3',6'-O,O'-diacetylfluorescein (CFSE) and propidium iodide (PI) were purchased from Nantong pharmaceutical Co., Ltd. (Jiangsu, China). The ACPP (EEEEEEEE-PLGLAG-RRRRRRRRN) was synthesized based on our design by Invitrogen Co., Ltd. (Shanghai, China). All other chemicals and reagents were purchased from Sigma Chemical Co. (St. Louis, MO, USA) and used as indicated.
Synthesis of HPMA copolymer
The monomers of HPMA, methacryloyl-glycyl-glycine p-nitrophenyl ester (MAGGONp), were synthesized according to previously published procedures [23], [24]. Copolymers (pHPMA-ONp) containing N-(2-hydroxy-propyl) methacryl amide (90 mol%) and methacryloyl-Gly-Gly-4-nitrophenoxy ester (10 mol%) with average molecular weight of 16500 were prepared as follows: a polymeric precursor containing reactive ONp estergroups (P') was synthesized by free radical precipitation copolymerization of the monomers of HPMA and MAGGONp in an acetone/DMSO mixture at 50°C for 24 h with 2,20-azobisisobutyronitrile (AIBN).
Cells and viruses
A549 human lung carcinoma cells and MDA-MB-231 human breast adenocarcinoma cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS) and 2 mM glutamine. Human bronchial epithelial (HBE) cells and HepG2 human hepatocarcinoma cells were grown in medium RRPMI-1640 supplemented with 10% fetal calf serum (FCS). The AdMax system was employed to generate adenovirus vectors. Recombinant Ad5 viruses with E1 and E3 deleted and expressing enhanced green fluorescent protein (eGFP) under the direction of the mCMV promoter, termed Ad-eGFP, were purified on CsCl gradients, and the viral titers were determined by a plaque assay and the titer was adjusted to 1.2×1012 plaque-forming units/ml.
RNA Preparation and RTFQ-PCR
Total RNA was extracted from human lung carcinoma cells A549,human breast adenocarcinoma cells MDA-MB-231, Human bronchial epithelial cells HBE and human hepatocarcinoma cells HepG2 with Trizol reagent (Invitrogen, USA) according to the manufacturer's instructions. The quantity of the RNA in the extraction was determined by measuring the absorbance ratio of A260 and A280 using spectrophotometer (Hitachi, Japan).For cDNA synthesis, 3.0 µg of total RNA was processed directly to cDNA by reverse transcription in 20 µL Prime Script RT Enzyme MixI (TAKARA, JPN) according to the manufacturer's protocol.
To quantify the RAGE mRNA expression in A549, MDA-MB-231, HBE, and HepG2, we performed RTFQ-PCR on a LightCycler (Bio-Rad CFX96, USA) using the SYBR Green method. Primers for MMP2 were designed to amplify 180 bp exon of genomic DNA (NM-004530: forward 5′- TGG CAA GTA CGG CTT CTG TC -3′, reverse 5′- TTC TTG TCG CGG TCG TAG TC-3′); Primers for MMP9 were designed to amplify 224 bp exon of genomic DNA (NM-004994: forward 5′- TGG GGG GCA ACT CGG C -3′, reverse 5′- GGAATGATCTAAGCCCAG -3′); Primers for GAPDH were designed to amplify 223 bp exon of genomic DNA (NM-002046: forward 5′- GAA GGT CGG AGT CAA CGG AT -3′, reverse 5′- CTG GAA GAT GGT GAT GGG AT -3′). RTFQ-PCR assay was performed in 50 µL reaction mixture with 25 µL SuperReal PreMix Plus, 10 µmol/L Forward primer, 1.5 µL reverse primer, 3 µL cDNA and 19 µL RNase-free ddH2O. The thermal cycles were: 1 cycle of 95°C for 15 min, followed by 40 cycles (for MMP9)or 35 cycles(for MMP2) at 95°C for 10 s, 60°C for 10 s, 72°C for 10 s for measuring fluorescence signals. In order to confirm the specificity of PCR products, inspection of agarose gel electrophoresis and the Alpha innotech softs were used. The mRNA expression level was presented as an OD ratio of MMP2 and MMP9 to that of GAPDH.
Protein isolation and measurement with western blot
For protein extraction, 106 cells of A549, MDA-MB-231, HBE and HepG2 were homogenized in lysis buffer containing 50 mM KCl, 250 mM cane sugar, 20 mM Tris–Cl, 100 mM NaCl, and 1 mM PMSF. The Protein Analyzer (Pharmacia Biotech, Piscataway,NJ, USA)was used to determine the total protein concentration. Each sample was loaded on an sodium dodecyl sulfate–poly -acrylamide electrophoresis gel and blotted with affinity-purified polyclonal antibodies specific for MMP-2 and MMP-9 (Santa CruzBiotech- nology, CA, USA),in 5% non-fat dry milk in Tris-buffered saline containing 0.1% Tween 20. After washed with PBS, the membranes were incubated with the corresponding second antibody. The resulted membranes were visualized using the LumiGLO Chemiluminescent Substrate solution (Cell Signaling,Danvers, MA, USA). The ratio of MMP-2 and MMP-9 to β-actin was used to evaluate protein mass as a function of SDS treatment.
Immunofluorescence
A549, MDA-MB-231, HepG2 and HBE cells were grown on coverslips and co-cultured with or without doxycycline (10 mg/L). After 48 h, cells were washed 3 times with cold PBS, followed with4% paraformaldehyde at 40′. The resulted cells were permeabilized in 0.1% Triton X-100 for 10 minutes before blocked in 5% bovine serum albumin in PBS for 30 minutes. Then the coverslips were stained with primary antibodies for MMP-2 (Santa CruzBiotech- nology, 1∶100), followed with Alexa 488 conjugated anti-rabbit secondary antibodies (Invitrogen, 1∶400). DAPI(Sigma)was used for nuclear counterstaining, while images were captured using an Nikon camera (LH-M100CB-1, Nikon, JP).
Effects of ACPP analysis
To determine the effects of MMPs on the activity of ACPP, A549, MDA-MB- 231,HBE and HepG2 cells (5×105) were aliquoted into 6-well plates after cultured at 37°C for 24 hours and treated with/without doxycycline at 10 µg/ml for 48 h. ACPP with a final concentrations of 200 umol/L was added to infect the cells for 4 hours. The media was then discarded, and the cells were washed with phosphate balanced solution (PBS, pH 7.0) six times. The FITC fluorescence images were recorded with a Nikon camera (LH-M100CB-1, Nikon, JP).
Virus modification
A random copolymer (pHPMA-ONp) was prepared and the coating of Ad5 particles was performed by adding 25 µL pHPMA-ONp (10 mg/ml in H2O) to 1010 Ad-eGFP particles in 100 ml 10% glycerol/PBS (pH 7.8), and incubated at 4°C for 12 h to form polymer-coated adenovirus (pc-Ad-eGFP). For the linkage of ACPPs, following an initial 2 h incubation of virus with pHPMA-ONp, ACPPs were added to a final concentration of 250 µg/ml and incubated for an additional 10 h to form ACPP-pc-Ad-eGFP. In characterization studies, the modified virus was purified from free polymer and free targeting agents using S400 spin columns 27-5140-01 (GE Healthcare).
Sizing of conjugates by dynamic light scattering (DLS)
Particle size after virus modification was measured by dynamic light scattering (DLS). Ad-eGFP (ZetaSizer, Malvern, UK) conjugates pc-Ad-eGFP and ACPP-pc-Ad-eGFP (1×1010 Ad5, 50 µl double distilled H2O) were mixed with 950 µl double distilled H2O. Particle sizing measurements were performed at a wavelength of 659.0 nm with a detection angle of 90° at RT.
Uptake and infectivity assays
Cells (104) were aliquoted into 96-well plates and infected 24 h later with 104 particles per cell of virus or modified virus in 200 µl DMEM with 10% FCS. Green fluorescent protein (GFP) expression was assessed by microscopy. A Nikon TI-S microscope was employed and images were recorded with a Nikon camera (LH-M100CB-1, Nikon, JP).
For quantitation of GFP fluorescence, the cells were lysed in 100 ml Triton X- 100 (0.2% v/v in 100 mM potassium phosphate, pH 7.8) in 96-well plates following the infection with Ad-eGFP and the conjugates for 48 h. GFP fluorescence (λex 488 nm and λem 538 nm) was measured with a Fluoroskan plate reader (Multiskan GO, Thermo Scientific) and expressed as relative fluorescence units (RFU).
FACS analysis was used to monitor infection of cells by the virus. A549 cells, at a concentration of (2×105 cells)/(2 ml DMEM/10% FCS), were incubated in 6-well plates at 37°C and allowed reach 90% confluence before the addition of 109 particles of Ad-eGFP, pc-Ad-eGFP or ACPP-pc-Ad-eGFP labeled with PI. Cells were trypsinized, centrifuged (2 min, 1500 g) and washed in PBS 48 h later. Association of PI-labeled virus with cells was measured using a FACS calibur flow cytometer with an argon laser (λex 540 nm and λem 625 nm).
For virus neutralization assays, human serum containing Ad5 neutralizing antibodies (NAb) was diluted 1∶20 in PBS and heated to 56°C for 20 min to inactivate complement. Diluted serum (100 µL) was then incubated with Ad-eGFP and ACPP-pc-Ad-eGFP at 37°C for 20 min before the culture medium was diluted to 108 particles/100 µL. Cells were washed once with PBS before virus solutions were added. After 48 h incubation, the A549 cells were plated in 96-well plates (104 cells per well) and the GFP expression of these samples was measured. The results expressed as the percentage of the signal obtained in the absence of human serum.
Retargeting polymer-coated adenovirus to alternative cancer cells
HBE, A549, MDA-MB-231 and HepG2 cells were seeded into 96-well plates (104 cells per well) and infected 24 h later with 104 particles per cell of retargeted virus in 200 µL DMEM supplemented with 10% FCS (A549, MDA-MB-231) or 200 µL RRPMI-1640 medium supplemented with 10% FCS (HBE, HepG2). For quantitation, the cells were lysed in 100 µL Triton X-100 (0.2% v/v in 100 mM potassium phosphate pH 7.8) and GFP fluorescence (λex 488 nm and λem 538 nm) was measured with a Fluoroskan plate reader (Multiskan GO, Thermo Scientific) and expressed as relative fluorescence units (RFU).
Intracellular distribution of conjugates
Cells plated on sterile coverslips in 6-well plates (2×105 cells per well) were grown for 24 h to reach 90% confluence. Cells were incubated with the ACPP-pc-Ad-eGFP conjugate or with pc-Ad-eGFP (which lacks the ACPP) for 1 h at 37°C. For localizations studies involving specific organelle markers(5- or6-(N-Succini- midyloxycarbonyl)-3',6'-O,O'-diacetylfluorescein,CFSE) and propidium iodide (PI) were employed. For studies of internalization, experiments included the incubation of cells with double-labeled conjugates: (FITC)ACPP-pc-Ad-eGFP(PI) or with pc-Ad-eGFP (PI). For the time-dependence studies, cells were incubated with ACPP-pc-Ad-eGFP (PI) or pc-Ad-eGFP(PI) for 20 min, 2 hr or 4 h. After all incubations, cells were washed thoroughly with PBS. The cells were visualized with a Nikon TI-S microscope and images recorded with a Nikon camera (LH-M100CB-1, Nikon, JP)
Results
mRNA and protein expression levels of MMP2and MMP9 were examined in cultured cell lines from A549, MDA-MB-231, HBE and HepG2. Unlike in HBE cell lines, both MMP2 mRNA and protein were overexpressed in these three cancer cell lines as indicated by the observed PCR products at the expected size of 180 bp (Figure 1) and the specific protein binding band at the expected size of 72 kDa (Figure 2). also In addition, RTFQ-PCR and western blot analysis revealed that the levels of both MMP9 mRNA and protein in the three cancer cell lines were higher than in HBE cell line, as indicated by the PCR products at the size of 224 bp (Figure 1) and the specific protein binding band at the size of 92 kDa (Figure 2). These results indicated the expressions of MMP2 and MMP9 were different in these 4 cell lines: overexpressed in cancer cells while under- expressed in HBE cell line for both mRNA and protein.
RTFQ-PCR analysis Left, a representative RTFQ-PCR; Right, shows quantitative data of MMP-2 and MMP-9 mRNA level, GAPDH was used as an internal control. Data are the means ± SEM. *P<0.05 compared with the HBE cell.
Left, a representative Western blot; Right, densitometric analysis of the representative Western blot, bars represent the relative amounts of MMP-2 and MMP-9. Data are the means ± SEM. *P<0.05 compared with the HBE cell.
MMPs are the best characterized soluble proteases in the overexpressed tumors and are responsible for the degradation of extracellular matrix. We integrated substrates(-PLGLAG-) as cleavable linkers between the polyanion inhibition (EEEEEEEE) and polycation sequence(RRRRRRRRN), so that the polycation peptide could be cleaved by MMPs and penetrate the MMP-overexpressing tumor cells, while in HBE cell line, such MMPs activities would be too low to conduct this enzyme cleavage, leading to no polycation peptide penetration. On the other hand, the MMPs-overexpressed cell lines treated with MMPs inhibitor doxycycline should have lower ACPP cell penetration because MMPs inhibitor doxycycline can decrease the MMPs level.
The immunofluorescence and ACPP penetration assay were performed to confirm this hypothesis. As shown in Figure 3, immunofluorescence staining displayed the high fluorescence intensity in A549, MDA-MB-231, HepG2 cells and light fluorescence intensity in HBE cell for MMP-2. After the cells were treated with doxycycline for 48 hours, the representative images of immunofluorescence staining in A549, MDA-MB-231, HepG2 cells showed that the immune-activity of MMP2 was dramatically reduced. In Figure 4, the FITC fluorescence of ACPP was strong in A549, MDA-MB-231, HepG2(Figure 4. a-c) while only weak FITC fluorescence could be observed in HBE cells(Figure 4. d).After the doxycycline treatment, the FITC fluorescence of ACPP decreased in A549,MDA-MB-231 and HepG2 cells(Figure 4. e-g), while there was no change on the FITC fluorescence of ACPP in HBE cells(Figure 4. h).
Immunofluorescence staining for MMP-2 (green) in cytoplasm and nucleus (blue) and merged image (blue-green) in A549, HepG2, MDA-MB-231 and HBE cells SP×200.A, C, E, G show A549, HepG2, MDA-MB-231 and HBE cells receiving no doxycycline treatment. B,D,F,H show the immunofluorescence images of MMP-2 in HepG2, HBE, A549, and MDA-MB-231 cells receiving doxycycline. Scale bar represents 100 px.
(A-C) A549, MDA-MB-231, HepG2 showed high FITC fluorescence of ACPP SP×200. (D) HBE showed low FITC fluorescence of ACPP SP×200. (E-H) FITC fluorescence of ACPP in A549, MDA-MB-231, HepG2 and HBE treated with Doxycycline SP×200.
The structure of the random copolymer (pHPMA-ONp) is shown in Scheme 1a in Figure 5. ACPP-pc-Ad-eGFP particles were synthesized and characterized. Polymer-coated Ad5 was prepared by mixing HPMA copolymer (Scheme 1b in Figure 5) with Ad5 and ACPPs (Scheme 1c in Figure 5) in 10% glycerol/PBS (pH 7.8), resulting in polymer molecules linked to each virus particle and ACPPs (Scheme 1d in Figure 5). FITC-labeled ACPPs were included in HPMA copolymers to assay the internalization of ACPPs. Analysis of particle size by dynamic light scattering (DLS) revealed that the average diameter of the unmodified virus was 141.8 nm (Figure 6a), compared with 189.4 nm for the pc-Ad-eGFP particles (Figure 6b) and 236.4 nm for the ACPP-pc-Ad-eGFP particles (Figure 6c).
(a) structure of pHPMA-ONp; scheme for virus modification involving (b) HPMA copolymers used for adenovirus polymer coating; (c) ACPPs used for targeting MMP-overexpressing tumor cells; (d) HPMA copolymers interact with adenovirus and ACPPs, forming a MMP-overexpressing tumor cells targeted polymer-coated adenovirus.
(a) the average size was found to be 141.8 nm for Ad-eGFP, (b) 189.4 nm for pc-Ad-eGFP, and (c) 236.4 nm for ACPP-pc-Ad-eGFP.
To test the ability of polymer-coated adenovirus to infect cells, the expression of green fluorescent protein (GFP), encoded by the recombinant Ad5 virus (Ad-eGFP), was assayed (Figure 7). When A549 human lung carcinoma cells were infected with 104 particles Ad-eGFP/cell, pc-Ad-eGFP displayed no detectable fluorescent signal at 24 h, while over 90% of A549 cells showed bright fluorescence after infection with ACPP-pc-Ad-eGFP (Figure 7A). Next, GFP expression was measured with a fluorescence plate reader (Figure 7B) to quantitatively measure the ability of the virus to infect A549 cells. We found that pc-Ad-eGFP infection was essentially ablated by the coating procedure, while ACPP-pc-Ad-eGFP penetrated the A549 cells successfully, showing little ablation of GFP expression.
(A) A549 cells were seeded into 96-well plates (104 cells/well) and infected after 24 h incubation with 104 particles per cell of Ad-eGFP, pc-Ad-eGFP and ACPP-pc-Ad-eGFP in DMEM/10% fetal calf serum (FCS). Cellular GFP fluorescence was visualized 48 h post-infection using a Nikon TI-S microscope and photographed with a Nikon camera. (i) Uninfected cells; infection with (ii) Ad-eGFP, (iii) pc-Ad-eGFP, and (iv) ACPP-pc-Ad-eGFP. (B) After A549 cells were infected for 48 h as described above, the medium was removed, the cells lysed with 100 ml Triton X-100 (0.2% in H2O) and GFP fluorescence was measured (λex 488 nm and λem 538 nm) with a Fluoroskan fluorescence plate reader (Multiskan GO, Thermo Scientific). The columns depict the following: (i) uninfected cells, (ii) Ad-eGFP, (iii) pc-Ad-eGFP, and (iv) ACPP-pc-Ad-eGFP. Data are the means ± SEM. *P<0.05 compared with i, #P<0.05 compared with iii (C) A549 cells were trypsinized, aliquoted at (2×105 cells)/(2 ml DMEM/10% FCS) and incubated in 6-well plates at 37°C until 90% confluence was reached; subsequently, 109 particles Ad-eGFP, pc-Ad-eGFP or ACPP-pc-Ad-eGFP labeled with PI were added. Cells were trypsinized, centrifuged (2 min, 1500 g) and washed in PBS 48 h later. Association of PI-labeled virus with cells was measured using a Coulter EPICS XL flow cytometer with an argon laser (λex 540 nm and λem 625 nm). The fluorescence profile of control cells (black line) or cells infected with virus (red line), pc-virus (yellow line) or ACPP-pc-virus (purple line).
To check the ability of polymer-coated virus to enter cells, the ability of ACPPs to mediate uptake of pc viruses into MMPs overexpressing cells was determined by flow cytometry of A549 cells following 4 h incubation at 37°C with RRPMI-1640, Ad-eGFP, pc- Ad-eGFP (PI) and ACPPs -pc- Ad-eGFP (PI).Uptake of pc-Ad-eGFP(PI) by A549 cells during 4 h incubation at 37°C was effectively abolished by the presence of the polymer coat. However, the ACPPs mediated uptake levelof pc-Ad-eGFP(PI) by A549 cells,which is similar to that of the unmodified Ad-eGFP (PI),seemed almost unaffected by the presence of the polymer coat. (Figure 6c), indicating that ACPPs facilitated the internalization of pc-Ad-eGFP.
The ability of ACPP-pc-Ad-eGFP to evade neutralizing antibodies was tested by examining the inhibition of adenoviral transduction. The modified virus was incubated with human serum known to contain anti-adenovirus neutralizing antibodies, and the polymer coating was found to protect the virus against NAb binding, while NAb significantly inhibited uncoated Ad5 transduction. Figure 8 shows that ACPP-pc-Ad-eGFP is 9-fold more resistant to neutralization than Ad-eGFP. Retargeted pc virus was less susceptible to inhibition of infection than the unmodified virus.
Ad-eGFP or ACPP-pc-Ad-eGFP (108 particles per 100 µl) was incubated with A549 cells in a 96-well plate (104 cells per well; 104 virus particles per cell) in the presence or absence of neutralizing antibodies (NAb). Expression of GFP was measured at 48 h after Triton X-100 lysis and was expressed as a percentage of the fluorescence signal in the absence of human serum. The yellow bar indicates Ad-eGFP, while the black bar denotes ACPP-pc-Ad-eGFP. Data are the means ± SEM. *P<0.05 compared with Ad-eGFP.
To test the feasibility of retargeting, ACPPs were chosen because these molecules had previously been shown to retarget cargoes to MMP-overexpressing cells. Targeting ACPPs were chemically attached to the reactive ester groups remaining on the surface of the pc virus, and this modified virus was purified from free polymer and free targeting agents using S400 spin columns 27-5140-01 as described previously. After HBE, A549, MDA-MB-231 and HepG2 cells were incubated with ACPP-pc-Ad-eGFP(PI) for 1 h at 37°C, the ability of ACPPs to target the MMP-overexpressing cells was determined by measuring GFP expression. Figure 9 shows that when cell lines were infected with this retargeted virus, the trend in cellular uptake of ACPP-pc-Ad-eGFP(PI) was as follows: A549, MDA-MB-231, HepG2 and HBE (ii, iii, iv and i, respectively). ACPP-pc-Ad-eGFP showed relatively low infectivity in HBE cells, while significantly enhanced GFP expression could be seen in A549, MDA-MB-231, and HepG2 cells, suggesting that selective infection in MMP-overexpressing tumor cells should be feasible.
HBE(control), A549, MDA-MB-231 and HepG2 cells were seeded into 96-well plates (104 cells per well) and after 24 h were infected with 104 particles per cell of ACPP-pc-Ad-eGFP in DMEM/10% FCS (A549, MDA-MB-231) or RRPMI-1640/10% FCS (HBE, HepG2). The supernatant was removed 4 h after infection and incubated with 200 µl DMEM/10% FCS (A549, MDA-MB-231) or RRPMI-1640/10% FCS (HBE, HepG2) for an additional 48 h before fluorescence was measured. The columns depict the following: i, HBE; ii, A549; iii, MDA-MB-231; and iv, HepG2. Data are the means ± SEM. *P<0.05 compared with the HBE cell.
Cytoplasmic delivery of ACPP-pc-Ad- eGFP was verified with the use of cytoplasm-specific markers. Cytoplasmic import was tested by co-incubating the cells with cytoplasmic marker CFSE (green fluorescence) and ACPP-pc-Ad-eGFP (PI) (red fluorescence). These dyes were found to co-localize resulting in a blue–red signal which demonstrated the cytoplasmic localization of the conjugate. CFSE (Figure 10A and 10B, green) and PI-labelled Ad-eGFP (Figure 10C and 10D, red) were separately visualized by fluorescence microscopy, and superimposition of the two dyes resulted in intracellular blue–red stained areas(Figure 10E and 10F, green–red), confirming the cytoplasmic delivery of ACPP-pc-Ad-eGFP and endocytotic uptake of pc-Ad-eGFP.
Inverted fluorescence microscopy image show(A, B) cytoplasmic marker CFSE (green), (C) incubated ACPP-pc-Ad-eGFP(PI) with A549 cells for 4 h at 37°C yielded uptake of the conjugate (red); (D) incubation pc-Ad-eGFP(PI) with A549 cells for 4 h at 37°C yielded little uptake (red); (E) superimposition of the two dyes (A and C) confirms ACPP-mediated nonendocytotic transport to the cytoplasm. (F) superimposition of the two dyes (Band D) exhibited only endocytotic vesicles. Scale bar represents 100 px.
The intracellular distribution of the ACPP-pc-Ad-eGFP was studied by fluorescence microscopy. A549 human lung carcinoma cells were incubated with fluorescein-labelled particles [(FITC)ACPP-pc-Ad-eGFP(PI)] for 4 h at 37°C (Figure 11). The ACPP-mediated internalization in the cytoplasm was inferred from diffuse staining visible within the cell body. The FITC on the ACPPs (Figure 11A, green) and the PI on the Ad-eGFP (Figure 11B, red) were separately tracked by fluorescence microscopy. The superimposition of these two dyes resulted in intracellular green-red stained areas (Figure 11C, green-red), which confirmed the cytoplasmic distribution of (FITC) ACPP-pc-Ad-eGFP(PI). These results are significant, as they demonstrate that the intracellular delivery of the conjugate ACPP-pc-Ad-eGFP was mediated by the ACPPs.
(A) cytoplasmic uptake of ACPP marker FITC (green); (B) cytoplasmic uptake of Ad-eGFP marker PI (red); (C) superimposition of the two dyes (green–red staining) confirms ACPP-mediated transport of pc-Ad-eGFP to the cytoplasm. Scale bar represents 100 px.
To investigate the time-dependence of the internalization process, Ad-eGFP was labeled with the fluorescent dye PI and employed in a fluorescence microscopy assay. Studies performed with ACPP-pc-Ad-eGFP(PI) at 37°C showed cytoplasmic uptake of Ad-eGFP(PI) at 20 min, 2 h and 4 h. The intensity of PI fluorescence was significantly stronger (Figure 12A-C) than that of the control pc-Ad-mda-7-eGFP particles lacking an ACPP (Figure 12D-F). Increasing the period of incubation with ACPP-pc-Ad-eGFP resulted in the cells showing a persistent increase in fluorescence intensity within the cytoplasm. The results indicate that the uptake of Ad-eGFP is time-dependent, with localization to the cytoplasm able to occur within 20 min.
Panels A-C depict the cytoplasmic uptake of ACPP-pc-Ad-eGFP at 20 min (A), 2 h (B), and 4 h (C). Panels d-f depict the cytoplasmic uptake of pc-Ad-eGFP at 20 min (D), 2 h (E), and 4 h (F). Scale bar represents 100 px.
Discussion
The use of ACPPs, which possess a targeting mechanism based on selective local separation from CPPs, is a flexible strategy that concentrates the therapeutic conjugates in the immediate vicinity of MMP-overexpressing solid tumors. By means of proteolytic activation of ACPP, we believe the use of pc-Ad- eGFP conjugates possesses several advantages. First, Uptake of most pc-Ad5 was observed to occur via endocytotic pathway and localized solely in vesicular compartments with no uptake into the cytoplasm,ACPP facilitated the penetration of the pc-Ad-eGFP through the cell membrane directly and the entry into the cytoplasm The localization in the cytoplasm of Ad-eGFP are important for effective expression of therapeutic adenovirus. Second, this system allows the diameter of the delivery cargo to be up to polymers of several nanometers [58]–[60]. As they are appended to the polycationic portion of ACPP, polymers, which often taken up by endocytosis, can be carried into the cytoplasm after linker cleavage. With the ACPPs, the excessive molecular mass overcomes the disadvantage of decreasing penetration into solid tumors with high interstitial fluid pressure. Third, it should be adaptable to a wide variety of solid tumors, as at least 26 members of the MMPs family have been identified, and they are the best characterized proteases overexpressed by tumors [61]–[65].
By modification of the surface of adenovirus with multivalent reactive 4-nitrophenoxy groups, pHPMA ablates their normal receptor binding properties, shields the virus from recognition by neutralizing antibodies, and permits incorporation of target molecules for virus retargeting. The convincing evidence that adenovirus can be targeted to MMP-overexpressing tumors and infect cells efficiently by means of proteolytic activation of cell-penetrating peptides has important implications for the intravenous administration of gene therapy vectors. Our finding that adenoviruses can be retargeted to MMP-overexpressing tumors provides an opportunity to refine their distribution kinetics and their tissue tropism in vivo, and permits the use of lower viral doses by avoiding CAR-mediated infection of non-target tissues. In addition, evidence of diminished neutralization by anti-adenovirus antibodies should enable the use of lower doses. We anticipate that this system will enable successful application of adenovirus gene therapy vectors with significantly decreased toxicity.
Acknowledgments
We are grateful to Yuan Huang for synthesis of pHPMA-ONp, Qingyu Xiang for the design and synthesis of ACPP, and Dongtin Zhou for expert assistance with flow cytometry.
Author Contributions
Conceived and designed the experiments: YZ. Performed the experiments: SL JC HX. Analyzed the data: SL JC YZ. Contributed reagents/materials/analysis tools: SL JC JL XX. Wrote the paper: SL.
References
- 1. Bergelson JM, Cunningham JA, Droguett G, Krithivas A et al (1997) Isolation of a common receptor for coxsackie B viruses and adeno -viruses 2 and 5. Science 275(5304): 1320–1323.
- 2. Peng Z, Yu Q, Bao L (2008) The application of gene therapy in China. IDrugs 11(5): 346–350.
- 3. Benihoud K, Yeh P, Perricaudet M (1999) Adenovirus vectors for gene delivery. Curr. Opin. Biotechnol 10(5): 440–447.
- 4. Campos SK, Barry MA (2007) Current advances and future challenges in adenoviral vector biology and targeting. Curr. Gene. Ther 7(3): 189–204..
- 5. Yang Y, Li Q, Ertl HCJ, Wilson JM (1995) Cellular and humoral immune responses to viral antigens create barriers to lungdirected gene therapy with recombinant adenoviruses. J Virol 69(4): 2004–2015.
- 6. Searle PF, Mautner V (1998) Adenoviral vectors: not to be sneezed at. Gene Therapy 5(6): 725–727.
- 7. Fasbender A, Zabner J, Chillon M, Moninger TOhttp://www.jbc.org/content/272/10/6479.short - aff-1, Puga APhttp://www.jbc.org/content/272/10/6479.short - aff-1, et al (1997) Complexes of adenovirus with polycationic polymers and cationic lipids increase the efficiency of gene transfer in vitro and in vivo. J Biol. Chem 272(10): 6479–6489.
- 8. Toyoda K, Nakane H, Heistad DD (2001) Cationic polymer and lipids augment adenovirus-mediated gene transfer to cerebral arteries in vivo. J Cereb. Blood Flow Metab 21(9): 1125–1131.
- 9. Kim PH, Kim TI, Yockman JW, Kim SW, Yun CO (2010) The effect of surface modification of adenovirus with an arginine-grafted bioreducible polymer on transduction efficiency and immunogenicity in cancer gene therapy. Biomaterials 31(7): 1865–1874.
- 10. Kasman LM, Barua S, Lu P, Rege K, Johnson CV (2009) Polymer-Enhanced adenoviral transduction of CAR-negative bladder cancer cells. Mol. Pharm 6(5): 1612–1619.
- 11. Dodds E, Piper TA, Murphy SJ, Dickson G (1999) Cationic lipids and polymers are able to enhance adenoviral infection of cultured mouse myotubes. J Neurochem 72(5): 2105–2112.
- 12. Singh R, Tian BW, Kostarelos K (2008) Artificial envelopment of nonen -veloped viruses: enhancing adenovirus tumor targeting in vivo. Faseb J 22(9): 3389–3402.
- 13. Park JW, Mok H, Park TG (2010) Physical adsorption of PEG grafted and blocked poly-L-lysine copolymers on adenovirus surface for enhanced gene transduction. J Control. Rel 142(2): 238–244.
- 14. Han J, Zhao D, Zhong Z, Zhang Z, Gong T, et al. (2010) Combination of adenovirus and cross-linked low molecular weight PEI improves efficiency of gene transduction. Nanotech 21(10): 105–106.
- 15. O'Riordan CR, Lachapelle A, Delgado C, Parkes V, Samuel C (1999) Wadsworth, Smith A E, Francis G E. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum. Gene. Ther 10(8): 1349–1358.
- 16. Croyle MA, Yu QC, Wilson JM (2000) Development of a rapid method for the PEGylation of adenovirus with enhanced transduction and improved stability under harsh storage conditions. Hum. Gene. Ther 11(12): 1713–1722.
- 17. Chillon M, Lee JH, Fasbender A, Welsh MJ (1998) Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro. Gene. Therapy 5(7): 995–1002.
- 18. Green NK, Herbert CW, Hale SJ, Hale AB, Mautner V, et al. (2004) Extended plasma circulation time and decreased toxicity of polymer- coated adenovirus. Gene. Ther 11(16): 1256–1263.
- 19. Fisher KD, Green NK, Hale A, Subr V, Ulbrich K, et al. (2007) Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy. J Drug. Target 15(7-8): 546–551.
- 20. Morrison J, Briggs SS, Green N, Fisher K, Subr V, et al. (2008) Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor. Mol. Ther 16(2): 244–251.
- 21. Green NK, Morrison J, Hale S, Briggs SS, Stevenson M, et al. (2008) Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer. J Gene. Med 10(3): 280–289.
- 22. Romanczuk H, Galer CE, Zabner J, Barsomian G, Wadsworth SC, et al. (1999) Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice. Hum Gene. Ther 10(16): 2615–2626.
- 23. Morrison J, Briggs SS, Green NK, Thoma C, Fisher KD, et al. (2009) Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer. Hum Gene. Ther 20(3): 239–251.
- 24. Ogawara K, Rots MG, Kok RJ, Moorlag HE, Van Loenen AM, et al. (2004) A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Hum Gene. Ther 15(5): 433–443.
- 25. Bachtarzi H, Stevenson M, Ubr V, Seymour LW, Fisher KD (2011) E-selectin is a viable route of infection for polymer-coated adenovirus retargeting in TNF-α-activated human umbilical vein endothelial cells. J Drug. Target 19(8): 690–700.
- 26. Willemsen RA, Pechar M, Carlisle RC, Schooten E, Pola R, et al. (2010) Multi-component polymeric system for tumour cell- specific gene delivery using a universal bungarotoxin linker. Pharm. Res 27(11): 2274–2282.
- 27. Xiang Q, Yang Y, Zhou Z, Zhou D, Jin Y, et al. (2012) Synthesis and in vitro anti-tumor activity of novel HPMA copolymer–drug conjugates with potential cell surface targeting property for carcinoma cells. European Journal of Pharmaceutics and Biopharmaceutics 80(2): 379–386.
- 28. Yang Y, Zhou Z, He S, Fan T, Jin Y, et al. (2012) Treatment of prostate carcinoma with (galectin-3)-targeted HPMA copolymer-(G3-C12)-5-Fluorouracil conjugates. Biomaterials 33(7): 2260–2271.
- 29. Wang CH, Chan LW, Johnson RN, Chu DS, Shi J, et al. (2011) The transduction of Coxsackie and Adenovirus Receptor-negative cells and protection against neutralizing antibodies by HPMA-co-oligolysine copolymer-coated adenovirus. Biomaterials 32(35): 9536–9545.
- 30. Nori A, Jensen KD, Tijerina M, Kopeckova P (2003) Subcellular trafficking of HPMA copolymer–Tat conjugates in human ovarian carcinoma cells. J of Control Rel 91(1-2): 53–59.
- 31. Green M, Loewenstein PM (1988) Autonomous functionaldomains of chemi- callly synthesized human immunodeficiency virus TAT trans-activator protein. Cell 55(6): 1179–1188.
- 32. Frankel AD, Pabo CO (1988) Cellular uptake of the TAT protein from human immunodeficiency virus, Cell. 55(6): 1189–1193.
- 33. Joliot A, Pernelle C, Deagostini-Bazin H, Prochiantz A (1991) Antennapedia homeobox peptide regulates neural morphogenesis. Proc. Natl. Acad. Sci 88(5): 1864–1868.
- 34. Elliott G, O'Hare P (1997) Intercellular trafficking and protein Delivery by a herpesvirus structural protein. Cell 88(2): 223–233.
- 35.
Oess S, Hildt E (2000) Novel cell permeable motif derived from the PreS2 -domain of hepatitis-B virus surface antigens, Gene. Ther 7 (9): 750–758.
- 36. Mi Z, Mai J, Lu X, Robbins PD (2000) Characterization of a class of cationic peptides able to faciliTATe efficient protein transduction in vitro and in vivo. Molec. Ther 2: 339–347.
- 37. Moy P, Daikh Y, Pepinsky B, Thomas D, Fawell S, et al. (1996) TAT-mediated protein delivery can facilitate MHC class I presentation of antigens. Mol Biotechnol6: 105–113.
- 38. Caron N J, Torrente Y, Camirand G, Bujold M, Chapdelaine P, et al. (2001) Intracellular delivery of a TAT–eGFP fusion protein into musclecells. Molec. Ther 3: 310–318.
- 39. Snyder EL, Dowdy SF (2001) Protein/peptide transduction domains: potential to deliver large DNA molecules into cells. Curr. Opin. Mol. Ther 3 (2): 147–152.
- 40. Rittner K, Benavente A, Bompard-Sorlet A, Heitz F, Divita G, et al. (2002) New basic membranedestabilizing peptides for plasmid- based gene delivery in vitro and in vivo. Molec. Ther 5: 104–114.
- 41. Mie M, Takahashi F, Funabashi H, Yanagida Y, Aizawa M, et al. (2003) Intracellular delivery of antibodies using TAT fusion protein A. Biochem Biophys Res Commun 310(3): 730–734.
- 42. Nori A, Jensen KD, Tijerina M, Kopeckova P, Kopecek J (2003) TAT-conjugated synthetic macromolecules faciliTATe cytoplasmic drug delivery to human ovarian carcinoma cells. Bioconjug. Chem 14(1): 44–50.
- 43. Josephson L, Tung CH, Moore A, Weissleder R (1999) High efficiency Intr -acellular magnetic labeling with novel superparamagnetic TAT pep -tide conjugates, Bioconjug. Chem 10(2): 186–191.
- 44. Torchilin VP, Rammohan R, Weissig V, Levchenko TS (2001) TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc. Natl. Acad Sci98(15): 8786–8791.
- 45. Jiang T, Olson E S, Nguyen Q T, Roy M, Jennings P A, et al. (2004) Tumor imaging by means of proteolytic activation of cell-penetrating peptide. PNAS101(51): 17867–17872.
- 46. Olson ES, Jiang T, Aguilera TA, Nguyen Q T, Ellies LG, et al. (2010) Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. PNAS 107 (9): 4311–4316.
- 47. Nguyen QT, Olson ES, Aguilera TA, Jiang T, Scadeng M, et al. (2010) Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. PNAS 107 (9): 4317–4322.
- 48. Bremer C, Tung CH, Weissleder R (2001) In vivo molecular target asse -ssment of matrix metalloproteinase inhibition. Nat. Med 7(6): 743–748.
- 49. Bremer C, Bredow S, Mahmood U, Bremer C, Bredow S, et al. (2001) Optical imaging of matrix metalloproteinase-2 activity in tumors: feasibility study in a mouse model. Radiology 221: 523–529.
- 50. Mattila T, Paakko P, Hujanen TT (2003) Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br. J. Cancer 89(7): 1270–1275.
- 51. La Rocca G, Pucci-Minafra I, Marrazzo A, Taormina P, Minafra S (2004) Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera.. Br J. Cancer 90(7): 1414–1421.
- 52. Ratnikov BI, DeryuginaE I, Strongin AY (2002) Gelatin zymography and substrate cleavage assays of matrix metalloproteinase-2 in breast carcinoma cells overexpressing membrane type-1 matrix metalloproteinase. Lab. Invest 82: 1583–1590.
- 53. Rejmanova P, Labsky J, Kopeček J (1977) Aminolyses of monomeric and polymeric p-nitrophenyl esters of methacryloylated amino acids,. Makromol. Chem 178: 2159–2168.
- 54. Rihova B, Bilej M, Vetvicka V (1989) Biocompatibility of N-(2-hydroxyl -propyl) methacrylamide copolymers containing adriamycin-immuno-genicity, And effect on hematopoietic stem cells in bone marrow in vivo and mouse spleenocytes and human peripheral blood lymphocytes in vitro. Biomaterials 10(5): 335–342.
- 55. Hitt MM, Ng P, Graham FL (2006) Construction and Propagation of Human Adenovirus Vectors. Cell Biology1: 435–443.
- 56. Fisher KD, Stallwood Y, Green NK, Ulbrich K, Mautner V, et al. (2001) Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther 8(5): 341–348.
- 57. Subr V, Kostka L, Selby-Milic T, Fisher K, Ulbrich K, et al. (2009) Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components. Journal of Controlled Release135: 152–158.
- 58. Lewin M, Carlesso N, Tung CH, Tang XW, Cory D, et al. (2000) Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat. Biotech 18(4): 410–414.
- 59. Torchilin VP, Levchenko TS (2003) TAT-liposomes: a novel intra- cellular drug carrier. Curr. Protein Pept. Sci 4(2): 133–140.
- 60. Zhao M, Kircher MF, Josephson L (2002) Weissleder R. Differential conjugation of tat peptide to superparamagnetic nanoparticles and its effect on cellular uptake Bioconjugate Chem. 13(4): 840–844.
- 61. Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T (2003) Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br. J.Cancer 89(7): 1270–1275.
- 62. Bremer C, Bredow S, Mahmood U, Weissleder R, Tung CH (2001) Optical Imaging of Matrix Metalloproteinase-2 Activity in Tumors: Feasibility Study in a Mouse Model. Radiology 221: 523–529.
- 63. La Rocca G, Pucci-Minafra I, Marrazzo A, Taormina P, Minafra S (2004) Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera.Br. J. Cancer 90(7): 1414–1421.
- 64. Ratnikov BI, Deryugina EI, Strongin AY (2002) Gelatin zymography and substrate cleavage assays of matrix metalloproteinase-2 in breast carcinoma cells overexpressing membrane type-1 matrix metalloproteinase. Lab. Invest 82 (11): 1583–1590.
- 65. Sounni N E, Janssen M, Foidart JM, Noel A (2003) Membrane type-1 matrix metalloproteinase and TIMP-2 in tumor angiogenesis. Matrix Biol 22(1): 55–61.